CapsoVision (CV) Stock Overview
A medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CapsoVision, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.19 |
| 52 Week High | US$15.37 |
| 52 Week Low | US$3.43 |
| Beta | 0 |
| 1 Month Change | 14.76% |
| 3 Month Change | 44.96% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 105.43% |
Recent News & Updates
Recent updates
AI Delays And Mounting R&D Costs Will Eventually Reward Capsule Endoscopy Adoption
Catalysts About CapsoVision CapsoVision develops wire free, cloud connected capsule endoscopy systems for gastrointestinal disease screening and diagnosis. What are the underlying business or industry changes driving this perspective?
Cloud And AI Capsule Endoscopy Will Reshape Long Term Prospects For This Undervalued GI Player
Catalysts About CapsoVision CapsoVision develops cloud connected capsule endoscopy systems that use panoramic imaging and AI to support noninvasive gastrointestinal screening and diagnostics. What are the underlying business or industry changes driving this perspective?Shareholder Returns
| CV | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.6% | -3.4% | 2.1% |
| 1Y | n/a | -21.0% | 30.6% |
Return vs Industry: Insufficient data to determine how CV performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how CV performed against the US Market.
Price Volatility
| CV volatility | |
|---|---|
| CV Average Weekly Movement | 14.1% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CV's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CV's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 99 | Johnny Wang | capsovision.com |
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services.
CapsoVision, Inc. Fundamentals Summary
| CV fundamental statistics | |
|---|---|
| Market cap | US$349.45m |
| Earnings (TTM) | -US$25.31m |
| Revenue (TTM) | US$13.55m |
Is CV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CV income statement (TTM) | |
|---|---|
| Revenue | US$13.55m |
| Cost of Revenue | US$6.38m |
| Gross Profit | US$7.17m |
| Other Expenses | US$32.49m |
| Earnings | -US$25.31m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 14, 2026
| Earnings per share (EPS) | -0.51 |
| Gross Margin | 52.92% |
| Net Profit Margin | -186.77% |
| Debt/Equity Ratio | 0% |
How did CV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/07 09:32 |
| End of Day Share Price | 2026/05/07 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CapsoVision, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Jason Wittes | Roth Capital Partners |
| Kyle Bauser | Roth Capital Partners |